FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096392044> ?p ?o ?g. }

• W3096392044 abstract "Summary Purpose The intermediate-risk (IR) prostate cancer (PCa) group is heterogeneous in terms of prognosis. For unfavorable or favorable IR PCa treated by radiotherapy, the optimal strategy remains to be defined. In routine practice, the physician's decision to propose hormonal therapy (HT) is controversial. The PROACT survey aimed to evaluate pattern and preferences of daily practice in France in this IR population. Materials and methods A web questionnaire was distributed to French radiotherapy members of 91 centers of the Groupe d’Etude des Tumeurs Uro-Genitales (GETUG). The questionnaire included four sections concerning: (i) the specialists who prescribe treatments and multidisciplinary decisions (MTD) validation; (ii) the definition of IR subsets of patients; (iii) radiotherapy parameters; (iv) the pattern of practice regarding cardiovascular (CV) and (iv) metabolic evaluation. A descriptive presentation of the results was used. Results Among the 82 responses (90% of the centers), HT schedules and irradiation techniques were validated by specific board meetings in 54% and 45% of the centers, respectively. Three-fourths (76%) of the centers identified a subset of IR patients for a dedicated strategy. The majority of centers consider PSA > 15 (77%) and/or Gleason 7 (4 + 3) (87%) for an unfavorable IR definition. Overall, 41% of the centers performed systematically a CV evaluation before HT prescription while 61% consider only CV history/status in defining the type of HT. LHRH agonists are more frequently prescribed in both favorable (70%) and unfavorable (98%) IR patients. Finally, weight (80%), metabolic profile (70%) and CV status (77%) of patients are considered for follow-up under HT. Conclusion To the best of our knowledge, this is the first survey on HT practice in IR PCa. The PROACT survey indicates that three-quarters of the respondents identify subsets of IR-patients in tailoring therapy. The CV status of the patient is considered in guiding the HT decision, its duration and type of drug." @default.
• W3096392044 created "2020-11-09" @default.
• W3096392044 creator A5000154528 @default.
• W3096392044 creator A5006422634 @default.
• W3096392044 creator A5012051564 @default.
• W3096392044 creator A5013153922 @default.
• W3096392044 creator A5014813898 @default.
• W3096392044 creator A5017893275 @default.
• W3096392044 creator A5023740879 @default.
• W3096392044 creator A5028353199 @default.
• W3096392044 creator A5031202796 @default.
• W3096392044 creator A5044502328 @default.
• W3096392044 creator A5046122596 @default.
• W3096392044 creator A5050184458 @default.
• W3096392044 creator A5054617918 @default.
• W3096392044 creator A5054669965 @default.
• W3096392044 creator A5063584845 @default.
• W3096392044 creator A5067708376 @default.
• W3096392044 creator A5071909609 @default.
• W3096392044 creator A5073583906 @default.
• W3096392044 creator A5079214434 @default.
• W3096392044 date "2020-12-01" @default.
• W3096392044 modified "2023-10-17" @default.
• W3096392044 title "Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group" @default.
• W3096392044 cites W1692684203 @default.
• W3096392044 cites W1847658388 @default.
• W3096392044 cites W1909369860 @default.
• W3096392044 cites W1984192990 @default.
• W3096392044 cites W1986114421 @default.
• W3096392044 cites W1988308740 @default.
• W3096392044 cites W2006286039 @default.
• W3096392044 cites W2008090769 @default.
• W3096392044 cites W2014251970 @default.
• W3096392044 cites W2014420251 @default.
• W3096392044 cites W2039377589 @default.
• W3096392044 cites W2041483836 @default.
• W3096392044 cites W2063266750 @default.
• W3096392044 cites W2065142831 @default.
• W3096392044 cites W2081052928 @default.
• W3096392044 cites W2082540132 @default.
• W3096392044 cites W2082647730 @default.
• W3096392044 cites W2086721180 @default.
• W3096392044 cites W2087107662 @default.
• W3096392044 cites W2089403922 @default.
• W3096392044 cites W2091346878 @default.
• W3096392044 cites W2092185710 @default.
• W3096392044 cites W2098998490 @default.
• W3096392044 cites W2099037568 @default.
• W3096392044 cites W2099051717 @default.
• W3096392044 cites W2102966185 @default.
• W3096392044 cites W2105310697 @default.
• W3096392044 cites W2108864389 @default.
• W3096392044 cites W2117792530 @default.
• W3096392044 cites W2125785593 @default.
• W3096392044 cites W2127345848 @default.
• W3096392044 cites W2130935668 @default.
• W3096392044 cites W2137372444 @default.
• W3096392044 cites W2140905531 @default.
• W3096392044 cites W2142359566 @default.
• W3096392044 cites W2148497849 @default.
• W3096392044 cites W2167949509 @default.
• W3096392044 cites W2169961966 @default.
• W3096392044 cites W2296809578 @default.
• W3096392044 cites W2318144531 @default.
• W3096392044 cites W2364135209 @default.
• W3096392044 cites W2511949746 @default.
• W3096392044 cites W2604801030 @default.
• W3096392044 doi "https://doi.org/10.1016/j.canrad.2020.03.014" @default.
• W3096392044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33144063" @default.
• W3096392044 hasPublicationYear "2020" @default.
• W3096392044 type Work @default.
• W3096392044 sameAs 3096392044 @default.
• W3096392044 citedByCount "1" @default.
• W3096392044 countsByYear W30963920442021 @default.
• W3096392044 crossrefType "journal-article" @default.
• W3096392044 hasAuthorship W3096392044A5000154528 @default.
• W3096392044 hasAuthorship W3096392044A5006422634 @default.
• W3096392044 hasAuthorship W3096392044A5012051564 @default.
• W3096392044 hasAuthorship W3096392044A5013153922 @default.
• W3096392044 hasAuthorship W3096392044A5014813898 @default.
• W3096392044 hasAuthorship W3096392044A5017893275 @default.
• W3096392044 hasAuthorship W3096392044A5023740879 @default.
• W3096392044 hasAuthorship W3096392044A5028353199 @default.
• W3096392044 hasAuthorship W3096392044A5031202796 @default.
• W3096392044 hasAuthorship W3096392044A5044502328 @default.
• W3096392044 hasAuthorship W3096392044A5046122596 @default.
• W3096392044 hasAuthorship W3096392044A5050184458 @default.
• W3096392044 hasAuthorship W3096392044A5054617918 @default.
• W3096392044 hasAuthorship W3096392044A5054669965 @default.
• W3096392044 hasAuthorship W3096392044A5063584845 @default.
• W3096392044 hasAuthorship W3096392044A5067708376 @default.
• W3096392044 hasAuthorship W3096392044A5071909609 @default.
• W3096392044 hasAuthorship W3096392044A5073583906 @default.
• W3096392044 hasAuthorship W3096392044A5079214434 @default.
• W3096392044 hasBestOaLocation W30963920441 @default.
• W3096392044 hasConcept C121608353 @default.
• W3096392044 hasConcept C126322002 @default.
• W3096392044 hasConcept C143998085 @default.
• W3096392044 hasConcept C19527891 @default.
• W3096392044 hasConcept C2777899217 @default.

• next